SOARW Volato Group, Inc.
Price Chart
Executive Summary
Volato Group entered into a securities purchase agreement to sell 6,500,000 shares of common stock at $0.34 per share for gross proceeds of approximately $2.21 million to Catheter Precision and other institutional investors. The company also announced a pivot to an AI-focused strategy, including evaluating non-binding AI infrastructure acquisition opportunities, after terminating a prior transaction with M2i Global. The capital raise provides near-term liquidity but is dilutive to existing shareholders, and the AI strategy shift carries significant execution risk with no definitive agreements in place.
Key Financial Metrics
Actionable Insight
Monitor for NYSE American approval of the supplemental listing application, which is a condition to closing. Watch for any definitive agreements on AI infrastructure acquisitions — the two non-binding LOIs could materialize into transactions that further dilute or transform the company. The 9-month Variable Rate Transaction ban limits certain toxic financing structures but does not preclude additional equity raises.
Key Facts
- Company sold 6,500,000 shares at $0.34/share for gross proceeds of ~$2.21 million
- Lead investor is Catheter Precision, Inc. (NYSE American: VTAK), which will also receive 451,901 freely tradeable shares of flyExclusive common stock
- Closing is subject to NYSE American approval of supplemental listing application
- Company terminated prior transaction with M2i Global and is now evaluating AI infrastructure acquisition opportunities
- Company received two unsolicited non-binding LOIs for potential AI-related transactions, but no definitive agreements have been executed
- 9-month prohibition on Variable Rate Transactions from the Effective Date
- Registration Rights Agreement requires filing of resale registration statement within 10 calendar days
Financial Impact
~$2.21 million gross proceeds from equity issuance; dilution of 6,500,000 shares at $0.34/share
Risk Factors
- Dilution from 6.5M new shares at $0.34/share
- No definitive AI acquisition agreements in place — strategy pivot is speculative
- NYSE American listing compliance risk — closing condition requires exchange approval
- Prior M2i Global transaction termination suggests deal execution challenges
- Company has been subject to Rule 144(i), indicating potential public information issues
Market Snapshot
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-027605 |
| Exhibit: ex10-2.htm | 0001493152-26-027605 |
| Exhibit: ex99-1.htm | 0001493152-26-027605 |
| Document: form8-k.htm | 0001493152-26-027605 |
| Document: 0001493152-26-027605-index-headers.html | 0001493152-26-027605 |
| Document: 0001493152-26-027605-index.html | 0001493152-26-027605 |
| Document: 0001493152-26-027605.txt | 0001493152-26-027605 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 8, 2026
5d ago
|
8-K
| — | awaiting T+20 | — | — |
|
Jun 5, 2026
7d ago
|
8-K
| — | awaiting T+20 | — | — |
|
May 11, 2026
4w ago
|
8-K
| — | awaiting T+20 | — | — |
|
Apr 28, 2026
6w ago
|
8-K
| — | awaiting T+20 | — | — |
|
Apr 22, 2026
7w ago
|
8-K
| — | awaiting T+20 | — | — |
|
Apr 17, 2026
8w ago
|
8-K
| — | awaiting T+20 | — | — |
|
Apr 13, 2026
8w ago
|
EFFECT
| — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access